Surface Marker Analysis of EBHX Lines
| Marker . | EBHX1 . | EBHX4 . | EBHX11 . | EBHX14 . | EBHX15 . |
|---|---|---|---|---|---|
| Precursors | |||||
| AA4.1-150 | 0.2 (0.8) | 0.5 (0.9) | 0.1 (0.6) | 7.6 (1.1) | 18.3 (3.2) |
| Sca-1 (Ly-6A)-150 | 0.4 (0.9) | 0.7 (0.8) | 0.1 (0.6) | 5.2 (1.4) | 1.1 (2.1) |
| Thy-1 | 6.8 (4.7) | 3.1 (4.3) | 0.3 (0.5) | 86.4 (30.7) | 99.4 (62.5) |
| FcγRII/III (CD32/CD16) | 78.2 (3.7) | 85.0 (5.4) | 0.1 (0.6) | 91.4 (5.7) | 99.7 (39.9) |
| CD44 | 91.5 (8.9) | 94.3 (10.2) | 98.1 (9.2) | 92.2 (7.7) | 16.9 (23.9) |
| VLA-4 (CD49d)-150 | 77.1 (3.4) | 98.0 (4.0) | 73.6 (1.2) | 99.5 (5.3) | 99.5 (20.4) |
| HSA (CD24)-150 | 0.1 (0.9) | 0.3 (0.8) | 99.7 (6.6) | 5.1 (2.3) | 98.5 (12.5) |
| Lineage-restricted | |||||
| TER-119-151 | 6.5 (1.8) | 0.8 (1.8) | 0.1 (0.7) | 13.4 (4.4) | 28.0 (8.6) |
| Mac-1 (CD11b) | 0.8 (1.8) | 0.2 (1.4) | 0.3 (0.6) | 4.1 (2.6) | 11.8 (12.1) |
| Gr-1 (Ly-6G) | 1.0 (1.7) | 0.4 (2.2) | 0.3 (0.5) | 23.2 (20.3) | 6.3 (31.5) |
| B220 (CD45R) | 1.2 (4.6) | 0.6 (2.4) | 0.3 (0.5) | 0.6 (1.6) | 0.4 (7.8) |
| Panleukocyte | |||||
| CD45 (Ly-5) | 1.2 (2.1) | 0.3 (2.1) | 0.2 (0.6) | 3.4 (2.3) | 84.8 (6.5) |
| CD18/CD11abc (LFA-1β2) | 96.8 (6.0) | 98.4 (7.2) | 0.3 (0.5) | 98.7 (10.1) | 98.5 (23.7) |
| ICAM-1 (CD54)-151 | 1.8 (2.2) | 0.4 (1.6) | 27.8 (1.7) | 0.7 (1.6) | 30.9 (9.2) |
| Marker . | EBHX1 . | EBHX4 . | EBHX11 . | EBHX14 . | EBHX15 . |
|---|---|---|---|---|---|
| Precursors | |||||
| AA4.1-150 | 0.2 (0.8) | 0.5 (0.9) | 0.1 (0.6) | 7.6 (1.1) | 18.3 (3.2) |
| Sca-1 (Ly-6A)-150 | 0.4 (0.9) | 0.7 (0.8) | 0.1 (0.6) | 5.2 (1.4) | 1.1 (2.1) |
| Thy-1 | 6.8 (4.7) | 3.1 (4.3) | 0.3 (0.5) | 86.4 (30.7) | 99.4 (62.5) |
| FcγRII/III (CD32/CD16) | 78.2 (3.7) | 85.0 (5.4) | 0.1 (0.6) | 91.4 (5.7) | 99.7 (39.9) |
| CD44 | 91.5 (8.9) | 94.3 (10.2) | 98.1 (9.2) | 92.2 (7.7) | 16.9 (23.9) |
| VLA-4 (CD49d)-150 | 77.1 (3.4) | 98.0 (4.0) | 73.6 (1.2) | 99.5 (5.3) | 99.5 (20.4) |
| HSA (CD24)-150 | 0.1 (0.9) | 0.3 (0.8) | 99.7 (6.6) | 5.1 (2.3) | 98.5 (12.5) |
| Lineage-restricted | |||||
| TER-119-151 | 6.5 (1.8) | 0.8 (1.8) | 0.1 (0.7) | 13.4 (4.4) | 28.0 (8.6) |
| Mac-1 (CD11b) | 0.8 (1.8) | 0.2 (1.4) | 0.3 (0.6) | 4.1 (2.6) | 11.8 (12.1) |
| Gr-1 (Ly-6G) | 1.0 (1.7) | 0.4 (2.2) | 0.3 (0.5) | 23.2 (20.3) | 6.3 (31.5) |
| B220 (CD45R) | 1.2 (4.6) | 0.6 (2.4) | 0.3 (0.5) | 0.6 (1.6) | 0.4 (7.8) |
| Panleukocyte | |||||
| CD45 (Ly-5) | 1.2 (2.1) | 0.3 (2.1) | 0.2 (0.6) | 3.4 (2.3) | 84.8 (6.5) |
| CD18/CD11abc (LFA-1β2) | 96.8 (6.0) | 98.4 (7.2) | 0.3 (0.5) | 98.7 (10.1) | 98.5 (23.7) |
| ICAM-1 (CD54)-151 | 1.8 (2.2) | 0.4 (1.6) | 27.8 (1.7) | 0.7 (1.6) | 30.9 (9.2) |
Results are the percentages of labeled cells (log mean fluorescence intensity) determined by direct staining of FcγRII/III-blocked cells with fluorescein isothiocyanate-conjugated antibodies.
Abbreviations: LFA, lymphocyte function-associated antigen; HSA, heat stable antigen; ICAM, intercellular adhesion molecule; Sca, stem cell antigen; VLA, very late antigen.
Direct staining of FcγRII/III-blocked cells with biotinylated antibodies and R-phycoerythrin-streptavidin.
Indirect staining with fluorescein isothiocyanate-conjugated secondary antibody (unblocked FcγRII/III).